Mafalda Oliveira News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer

Ipatasertib plus trastuzumab and pertuzumab as frontline maintenance therapy was effective and safe in PIK3CA-mutant, HER2-positive advanced breast cancer.

Comunidad autonoma de catalunaIsrael generalDaiichi sankyo astrazenecaMafalda oliveiraBreast cancer congressHebron university hospitalBreast cancer groupHebron institute of oncologyOncology department of the breast cancer groupAyala pharmaceuticalsMedical oncology departmentUniversity hospitalHebron instituteZenith epigeneticsCureos scienceRelay therapeutics

CHMP meeting highlights: April 2024

CHMP meeting highlights: April 2024
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Israel generalComunidad autonoma de catalunaMafalda oliveiraAstrazeneca truqapReyataz atazanavirEribulin baxterCommittee for human medicinal productsDepartment of medical oncologyHebron university hospitalHebron institute of oncologyBreast cancer groupHuman medicinal productsSenior consultantMedical oncologySenior clinical investigatorHebron institute

AstraZeneca: CHMP green light for Truqap + Faslodex

AstraZeneca announces that Truqap in combination with Faslodex has been recommended by the Committee for Medicinal Products for Human Use of the European Medicines Agency for approval in the.

Israel generalComunidad autonoma de catalunaMafalda oliveiraHebron oncology instituteEuropean unionCommittee for medicinal products human useBreast cancer groupDepartment of medical oncology at vallEuropean medicines agencyHebron university hospitalMedicinal productsHuman useSenior consultantMedical oncologySenior clinical researcher

CHMP Recommends Capivasertib/Fulvestrant for Pretreated ER+/HER2– Advanced Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

The EMA’s CHMP recommended capivasertib/fulvestrant for ER-positive, HER2-negative advanced breast cancer harboring PIK3CA, AKT1, or PTEN alterations.

Israel generalComunidad autonoma de catalunaMafalda oliveiraDepartment of medical oncology at vallHebron university hospitalHebron institute of oncology breast cancer groupEuropean medicines agencyMedicinal productsHuman useMedical oncologyHebron instituteBreast cancer groupEr positive breast cancerPik3ca alterationsAkt1 alterationsPten alterations

Truqap Plus Faslodex Boosts Breast Cancer Outcomes, Quality of Life

Patients with HR-positive, HER2-negative breast cancer tended to have longer health-related quality of life and improved outcomes with Truqap plus Faslodex, research showed.

San antonioUnited statesTruqap faslodexMafalda oliveiraTruqap faslodecDepartment of medical oncology at vallHebron university hospitalAntonio breast cancer symposiumPatient global impressionTruqap faslodex offersMore optionSome with breast cancerMedical oncologyTreatment tolerabilityBreast cancer